Skip to main content

Table 1 Demographics

From: Are patients with high-risk polycythemia vera receiving cytoreductive medications? A retrospective analysis of real-world data

 

Low-risk PV (n = 1033)

High-risk PV (n = 1823)

All patients (N = 2856)

Mean (SD) age, years

49.7 (8.6)

69.7 (9.9)

62.5 (13.5)

Age group, n (%), years

 18–34

73 (7.1)

5 (0.3)

78 (2.7)

 35–54

573 (55.5)

86 (4.7)

659 (23.1)

 55–64

387 (37.5)

522 (28.6)

909 (31.8)

  ≥ 65

NA

1210 (66.4)

1210 (42.4)

Sex, n (%)

 Male

757 (73.3)

1125 (61.7)

1882 (65.9)

 Female

276 (26.7)

698 (38.3)

974 (34.1)

Geographic region, n (%)

 South

402 (38.9)

558 (30.6)

960 (33.6)

 North Central

230 (22.3)

499 (27.4)

729 (25.5)

 Northeast

218 (21.1)

482 (26.4)

700 (24.5)

 West

169 (16.4)

270 (14.8)

439 (15.4)

 Unknown

14 (1.4)

14 (0.8)

28 (1.0)

Insurance payer, n (%)

 Commercial

1033 (100)

613 (33.6)

1646 (57.6)

 Medicare

0

1210 (66.4)

1210 (42.4)

Insurance plan type, n (%)

 PPO

669 (64.8)

943 (51.7)

1612 (56.4)

 Comprehensive

47 (4.5)

576 (31.6)

623 (21.8)

 HMO

106 (10.3)

150 (8.2)

256 (9.0)

 POS

83 (8.0)

70 (3.8)

153 (5.4)

 CDHP

72 (7.0)

37 (2.0)

109 (3.8)

 HDHP

32 (3.1)

13 (0.7)

45 (1.6)

 EPO

6 (0.6)

18 (1.0)

24 (0.8)

 POS with capitation

7 (0.7)

2 (0.1)

9 (0.3)

 Unknown

11 (1.1)

14 (0.8)

25 (0.9)

  1. Data assessed on the index date (January 1, 2013)
  2. CDHP consumer-driven health plan, EPO exclusive provider organization, HDHP high-deductible health plan, HMO health maintenance organization, NA not applicable, POS point of service, PPO preferred provider organization, PV polycythemia vera, SD standard deviation